https://orcid.org/0000-0002-4626-4218
References
- Zhdanava M, Starr HL, Totev TI, et al. Impact of COVID-19 pandemic on prescribing of long-acting injectable antipsychotics for schizophrenia: results from a United States prescriber survey. Neuropsychiatr Dis Treat. 2022;18:2003–2019. doi:10.2147/NDT.S379985
- Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2020;34(6):579–598. doi:10.1007/s40263-020-00713-9
- Oguchi Y, Miyake N, Ando K. Maintenance treatment for schizophrenia during the COVID-19 pandemic: the views of Japanese psychiatrists. Clin Neuropsychopharmacol Ther. 2021;12:6–8. doi:10.5234/cnpt.12.6
- Ifteni P, Dima L, Teodorescu A. Long-acting injectable antipsychotics treatment during COVID-19 pandemic – a new challenge. Schizophr Res. 2020;220:265–266. doi:10.1016/j.schres.2020.04.030
- Weiden PJ, Kim E, Bermak J, Turkoz I, Gopal S, Berwaerts J. Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone. J Clin Psychiatry. 2017;78(7):e813–e820. doi:10.4088/JCP.16m11308